首页> 外文期刊>Nature >Control of mammary stem cell function by steroid hormone signalling
【24h】

Control of mammary stem cell function by steroid hormone signalling

机译:通过类固醇激素信号传导控制乳腺干细胞功能

获取原文
获取原文并翻译 | 示例
       

摘要

The ovarian hormones oestrogen and progesterone profoundly influence breast cancer risk, underpinning the benefit of endocrine therapies in the treatment of breast cancer. Modulation of their effects through ovarian ablation or chemoprevention strategies also significantly decreases breast cancer incidence. Conversely, there is an increased risk of breast cancer associated with pregnancy in the short term. The cellular mechanisms underlying these observations, however, are poorly defined. Here we demonstrate that mouse mammary stem cells (MaSCs) are highly responsive to steroid hormone signalling, despite lacking the oestrogen and progesterone receptors. Ovariectomy markedly diminished MaSC number and outgrowth potential in vivo, whereas MaSC activity increased in mice treated with oestrogen plus progesterone. Notably, even three weeks of treatment with the aromatase inhibitor letrozole was sufficient to reduce the MaSC pool. In contrast, pregnancy led to a transient 11 -fold increase in MaSC numbers, probably mediated through paracrine signalling from RANK ligand. The augmented MaSC pool indicates a cellular basis for the short-term increase in breast cancer incidence that accompanies pregnancy. These findings further indicate that breast cancer chemoprevention may be achieved, in part, through suppression of MaSC function.
机译:卵巢激素雌激素和孕酮深刻影响乳腺癌的风险,巩固了内分泌疗法在乳腺癌治疗中的优势。通过卵巢消融或化学预防策略调节其作用还可以显着降低乳腺癌的发病率。相反,短期内与妊娠相关的乳腺癌风险增加。然而,这些观察结果的细胞机制定义不清。在这里,我们证明,尽管缺乏雌激素和孕激素受体,小鼠乳腺干细胞(MaSCs)对类固醇激素信号传导高度敏感。卵巢切除术显着减少了体内的MaSC数量和增生潜力,而MaSC活性在雌激素加孕激素治疗的小鼠中增加。值得注意的是,即使用芳香酶抑制剂来曲唑治疗三周也足以减少MaSC库。相反,怀孕导致MaSC数量短暂增加11倍,可能是通过RANK配体的旁分泌信号传导介导的。增强的MaSC库表明,伴随怀孕的乳腺癌发病率短期增加的细胞基础。这些发现进一步表明乳腺癌化学预防可以部分地通过抑制MaSC功能来实现。

著录项

  • 来源
    《Nature》 |2010年第7299期|798-802|共5页
  • 作者单位

    The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia;

    rnThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia;

    rnThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia;

    rnThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia;

    rnThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia Department of Medical Biology, The University of Melbourne, Parkville, Victoria 3010, Australia;

    rnPrince Henry's Institute of Medical Research, Monash Medical Centre, Clayton, Victoria 3168, Australia;

    rnNagahama Institute for Biochemical Science, Oriental Yeast Company, Nagahama, Shiga 526-0804, Japan;

    rnThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia Department of Medical Biology, The University of Melbourne, Parkville, Victoria 3010, Australia;

    rnSt Vincent's Institute, Fitzroy, Victoria 3065, Australia;

    rnThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia Department of Medical Oncology, The Royal Melbourne Hospital, Parkville, Victoria 3050, Australia Department of Medicine, The University of Melbourne, Parkville, Victoria 3010, Australia;

    rnThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australia Department of Medical Biology, The University of Melbourne, Parkville, Victoria 3010, Australia;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 02:55:06

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号